Aurinia Pharmaceuticals (NASDAQ:AUPH) Issues Earnings Results

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) issued its quarterly earnings results on Thursday. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.04, FiscalAI reports. Aurinia Pharmaceuticals had a return on equity of 27.53% and a net margin of 100.84%.The firm had revenue of $58.57 million during the quarter, compared to analyst estimates of $81.79 million.

Aurinia Pharmaceuticals Trading Down 1.7%

AUPH opened at $15.85 on Friday. Aurinia Pharmaceuticals has a one year low of $10.34 and a one year high of $19.25. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.55 and a quick ratio of 5.01. The business has a 50 day simple moving average of $15.95 and a two-hundred day simple moving average of $15.35. The firm has a market capitalization of $2.04 billion, a price-to-earnings ratio of 6.92 and a beta of 1.42.

Wall Street Analysts Forecast Growth

AUPH has been the topic of a number of research reports. Wall Street Zen cut Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday. Royal Bank Of Canada boosted their target price on Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the stock a “sector perform” rating in a research report on Friday. Zacks Research lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 21st. Finally, Weiss Ratings cut shares of Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, May 15th. One equities research analyst has rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $17.67.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, CEO Kevin Tang bought 206,005 shares of Aurinia Pharmaceuticals stock in a transaction dated Tuesday, June 2nd. The shares were purchased at an average cost of $15.28 per share, with a total value of $3,147,756.40. Following the completion of the purchase, the chief executive officer owned 13,044,106 shares of the company’s stock, valued at approximately $199,313,939.68. This represents a 1.60% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders purchased 814,606 shares of company stock valued at $12,455,129. 10.40% of the stock is currently owned by company insiders.

Institutional Trading of Aurinia Pharmaceuticals

Several large investors have recently added to or reduced their stakes in AUPH. Northwestern Mutual Wealth Management Co. bought a new position in Aurinia Pharmaceuticals in the 3rd quarter worth $48,000. Kemnay Advisory Services Inc. bought a new stake in shares of Aurinia Pharmaceuticals during the 4th quarter valued at about $82,000. BNP Paribas Financial Markets boosted its stake in shares of Aurinia Pharmaceuticals by 32.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 13,034 shares of the biotechnology company’s stock valued at $110,000 after purchasing an additional 3,191 shares in the last quarter. CIBC Bancorp USA Inc. purchased a new position in shares of Aurinia Pharmaceuticals during the third quarter valued at about $137,000. Finally, Engineers Gate Manager LP purchased a new position in shares of Aurinia Pharmaceuticals during the second quarter valued at about $162,000. Institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.